Imatinib Stada (Imatinib)

Imatinib acts on malignant cells driven by specific tyrosine‑kinase pathways, providing targeted therapy for several hematologic and solid tumours.

• Chronic myeloid leukemia (CML): Suppresses BCR‑ABL positive leukemic proliferation and improves survival.
• Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): Reduces disease burden by inhibiting the same oncogenic kinase.
• Gastrointestinal stromal tumor (GIST): Blocks c‑KIT and PDGFR signaling to limit tumor growth.

• Imatinib selectively inhibits the BCR‑ABL tyrosine kinase produced by the Philadelphia chromosome translocation, and also blocks the activity of c‑KIT and platelet‑derived growth factor receptors (PDGFR). By preventing phosphorylation of downstream signaling proteins, it halts uncontrolled cell division and induces apoptosis in malignant cells that depend on these pathways.

Imatinib may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Edema: peripheral swelling, often in the ankles.
• Muscle cramps: intermittent stiffness or pain.
• Fatigue: reduced energy levels.
• Diarrhea: loose stools, sometimes watery.
• Rash: mild skin irritation.

Serious or Rare Side Effects

• Neutropenia: significant drop in white blood cells.
• Thrombocytopenia: low platelet count leading to bleeding risk.
• Hepatotoxicity: elevated liver enzymes or liver injury.
• Cardiac failure: reduced heart function, especially in patients with pre‑existing disease.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Pulmonary hypertension: increased pressure in lung arteries.

Before initiating therapy, clinicians should assess patient‑specific factors and monitor for potential complications.

• Hepatic impairment: Adjust dose based on liver function tests.
• Renal impairment: Monitor renal function and consider dose modification.
• Cardiovascular disease: Evaluate baseline cardiac status; watch for signs of heart failure.
• Concomitant anticoagulants: Monitor coagulation parameters closely.
• Pregnancy and lactation: Use only if potential benefit justifies potential risk; data are limited.
• Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and light.

Imatinib interacts with several drug classes that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): May raise imatinib levels.
• Azole antifungals (e.g., itraconazole): Increase exposure and risk of adverse events.
• Grapefruit juice: Potentiates CYP3A4 inhibition, raising drug concentrations.
• Proton pump inhibitors (high dose): Can reduce absorption.
• Certain antiretrovirals (e.g., ritonavir): Significantly elevate plasma levels.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampicin, carbamazepine): May lower efficacy.
• Warfarin: Potential for altered INR; monitor coagulation.
• Diuretics: May exacerbate fluid retention.
• Vaccines (live attenuated): Assess risk‑benefit before administration.